Tuesday, July 1, 2025 7/1/2025

AN INNOVATIVE CARDIOPROTECTIVE

Award Number: R43HL114298
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/05/2012
PERIOD OF PERFORMANCE END DATE: 03/31/2013

Group Awards By:

View Award Description

AN INNOVATIVE CARDIOPROTECTIVE - DESCRIPTION (provided by applicant): Myocardial infarction (MI) is a significant cause of morbidity and mortality in the U.S. H2 Relaxin (H2R) is a Phase III clinical trial-stage peptide that exhibits both anti-inflammatory and cytoprotective activities which can potentially be harnessed for the treatment of MI via use as adjuvant to recanalization therapy. However, clinical administration of rhH2R is not only prohibitively expensive but also plagued by numerous logistical issues. To fully capitalize on the therapeutic potential of the H2R pathway while overcoming the afore-mentioned shortcomings, Angion Biomedica Corp. has developed a library of chemically synthesizable H2R-like peptides. In preliminary studies, ANG-4011, our lead H2R-like peptide demonstrated significant tissue protective effects. The present Phase 1 SBIR proposal is designed to fully optimize the therapeutic effects of ANG-4011 in experimental myocardial ischemia-reperfusion injury. Data from this program will form the basis for a comprehensive SBIR Phase II program goals for which include optimization of ANG-4011 delivery in sustained-release, clinically compatible, biodegradable microspheres, evaluation of ANG-4011 therapy in myocardial-reperfusion models accompanied by co-morbidities (e.g. age and diabetes) and ANG-4011 safety/toxicology evaluation. The overall objective of this program is to bring potentially promising therapeutic to clinical trials for patients presenting with MI. PUBLIC HEALTH RELEVANCE: Myocardial infarction remains a significant cause of morbidity and mortality. A cardioprotective agent that reduces infarct size and salvages myocardium can avert the transition to pump failure.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2012 ( Subtotal = $373,934 )
2012	2012	ANGION BIOMEDICA CORPORATION	350 COMMUNITY DRIVE	MANHASSET	NY	11030	NASSAU	USA	Cardiovascular Diseases Research	000	1	4/4/2012	NEW	$373,934
														Subtotal = $373,934

Grand Total All Awards = $373,934

Top

All Categories

About

Search

Reports

Data Submission

Award Information

AN INNOVATIVE CARDIOPROTECTIVE

Award Number: R43HL114298

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/05/2012

PERIOD OF PERFORMANCE END DATE: 03/31/2013

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer